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ABSTRACT: Pseudomonas aeruginosa and Acinetobacter species are the primary cause of nosocomial 
infections. The advent of Metallo-beta-lactamase (MBL) and biofilm-producing bacterial strains poses a 
serious threat to reserve drugs such as carbapenem. The objective of this study was to determine the rate of 
MBL and biofilm production among imipenem resistant P. aeruginosa (IRPA) and imipenem resistant 
Acinetobacter spp. (IRAS) isolates. A total of 79 P. aeruginosa and 117 Acinetobacter spp. were isolated from 
various clinical specimens of patients from July 2016 to January 2017 at Manipal Teaching Hospital, Pokhara. 
MBL in IRPA and IRAS isolates were detected by Combined disc test and E-test. Biofilm production in 
imipenem resistant isolates was carried out by Microtitre plate assay. Fifteen (19%) P. aeruginosa and 57 
(48.7%) Acinetobacter spp. were imipenem resistant isolates. MBL producers were found among 53.3% of 
IRPA and 38.6% of IRAS, whereas 100% of IRPA and 82.5% of IRAS were biofilm producers. All the biofilm 
producer IRPA isolates were Extensively Drug-Resistant (XDR), and a larger proportion of XDR IRAS strains 
were of high biofilm-producing phenotype. However, the majority of imipenem resistant (80% of IRPA and 
49.1% of IRAS) and MBL producing (63%) isolates were weak biofilm formers. The study demonstrated the 
high capability of IRPA and IRAS to form a biofilm, which was strongly related to higher drug resistance. 
Nonetheless, imipenem resistant and MBL producer isolates showed an analogous association with the degree 
of biofilm formation. These MBL cum biofilm producer isolates were better susceptible to polymyxin B and 
ampicillin-sulbactam.  
Keywords: Pseudomonas aeruginosa; Acinetobacter spp.; Imipenem-resistance; MBL; Biofilm. 
1. INTRODUCTION 
Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter species are an emerging cause of 
the hospital-acquired infection that presents a serious public health threat [1]. High carbapenem resistance in 
these organisms can be mediated by porin loss and efflux pumps or via carbapenemases [2]. Among various 
mechanisms of carbapenem resistance in P. aeruginosa, the production of MBLs is of particular concern due 
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to their rapid spread, the effectiveness of carbapenemase, resistance to β-lactamase inhibitors and the ability 
to hydrolyze all β-lactam antibiotics except aztreonam [3]. 
P. aeruginosa and Acinetobacter spp. are more resistant to antibiotics than other Gram-negative 
bacteria because of their high ability to form biofilm [4]. Extracellular polymeric substance (EPS) of biofilm 
acts as a defensive armor that prevents the diffusion of antibiotics [5]. Moreover, the frequent transfer of 
antibiotic resistance genes takes place among the biofilm cells. Therefore, MBL activity with biofilm 
formation in P. aeruginosa and Acinetobacter spp. can lead to ineffective antimicrobial therapy [6].  
Though it is of utmost importance to screen biofilm production and antimicrobial resistance pattern 
among these bacteria, limited information is available on this issue from Nepal. The objective of this study 
was to determine the rates of biofilm and MBL production among imipenem resistant P. aeruginosa and 
Acinetobacter spp. Further, we determined the rate of MDR and XDR among the strains of. P. aeruginosa and 
Acinetobacter spp. 
2. MATERIALS AND METHODS 
2.1. Bacterial strains 
The study was conducted in the Manipal Teaching Hospital (MTH), Pokhara, a tertiary care hospital in 
western Nepal from July 2016 to January 2017. The study included inpatient and outpatient departments of all 
age groups and both genders visiting MTH. P. aeruginosa and Acinetobacter spp. were isolated from various 
clinical specimens like respiratory specimens, blood, and other body fluids, urine, pus, and indwelling 
catheters. The bacterial isolates were identified as per standard microbiological techniques [7]. 
2.2. Antibiotic susceptibility test 
Antimicrobial susceptibility testing of the isolates was performed on Mueller Hinton Agar (HiMedia, 
Mumbai, India) by Kirby-Bauer disc-diffusion method and interpreted following Clinical and Laboratory 
Standard Institute (CLSI, 2014) guidelines [8]. The isolates resistant to at least one agent in three or more 
antimicrobial categories were labeled as Multidrug-Resistant (MDR). The isolates resistant to at least one 
agent in all but susceptible to only one or two categories were defined as Extensively Drug-Resistant                 
(XDR) [9].  
2.3. Detection of MBL production 
The imipenem-ethylenediamine tetra-acetic acid (EDTA) disk diffusion test [10] and 
imipenem/imipenem + EDTA E-test according to manufacturer’s instruction [8] were used to detect MBL 
production among all the isolates that showed reduced susceptibility to imipenem. EDTA and E-test strips 
were obtained from Hi-media, India. Quality control of E-test strips was carried out by testing the strips with 
P. aeruginosa ATCC 27853 recommended by CLSI, 2014 [8]. 
2.4. Biofilm detection 
Biofilm production (biomass) was detected among imipenem resistant isolates by microtiter plate 
(MTP) assay in accordance with the Christensen et al. [11] technique improvised by Stepanovic et al. [12]. 
Overnight cultures of bacteria in Brain Heart Infusion (BHI) broth with 1% glucose were standardized to 0.5 
McFarland standard (~108 CFU/ml). Each well of commercially procurable pre-sterilized polystyrene 96 wells 
tissue culture plates (HiMedia, Mumbai, India) were filled with 180 µl of sterile BHI broth supplemented with 
1% glucose. After that, a thorough vortexed 20 µl of already prepared bacterial suspensions were added to 
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each well resulting in the final testing inoculums of ~106 CFU/ml. Ten different wells containing sterilized 
200 µl BHI broth with 1% glucose supplied as controls. The inoculated plate was covered with a lid and 
incubated at 37°C for 24 hours aerobically. The wells were washed four times with sterile phosphate buffer 
saline (pH 7.2), fixed with Bouin’s fluid (saturated solution of picric acid 75 parts, formaldehyde 25 parts, and 
glacial acetic acid five parts) followed by washing once with sterile PBS, drying and then stained with 0.1% 
crystal violet solution. Excess stain was removed by tapping the plate. The plate was then left at room 
temperature for 15 min, followed by washing three times. Henceforth, 200 µl of 95% ethanol was added to 
each well. 150 µl of the solution from each well was transferred to another microtiter plate. The absorbance 
was measured at 630 nm using ELISA reader (HumaReader HS, Human, Germany). Biofilm producer and 
biofilm non-producer standard strains of P. aeruginosa served as positive and negative controls, respectively. 
The cut off absorbance (ODC) value was considered as three times the standard deviation above the mean 
optical density (OD) of the control. Biofilm positive isolates were characterized as strong, moderate, and 
weak. The categories were based on the following criteria; non-biofilm producer if OD ≤ ODc, weak biofilm 
producer if ODc < OD ≤ 2ODc, moderate biofilm producer if 2 ODc < OD ≤ 4 ODc, and strong biofilm 
producer if 4 ODc < OD [12]. 
3. RESULTS 
P. aeruginosa strains exhibited very high resistance rates towards piperacillin-tazobactam (89.9%), 
followed by ceftazidime (73.4%). The percentage resistance of P. aeruginosa isolates towards meropenem and 
imipenem was 27.8% and 19.0%, respectively (Table 1). Among 79 P. aeruginosa evaluated, 9 (11.4%) were 
MDR, 22 (27.8%) were XDR, and 48 (60.8%) were NMDR (Non-Multidrug-Resistant). All the imipenem 
resistant strains were XDR. The isolates exhibited discrepant carbapenem susceptibility profile; 8 isolates of 
P. aeruginosa were imipenem susceptible meropenem resistant, 1 was imipenem resistant meropenem 
susceptible, and 14 were both imipenem and meropenem resistant. All P. aeruginosa isolates were susceptible 
to polymyxin B (Table 1). 
 
Table 1. Antibiotic resistance pattern of P. aeruginosa and Acinetobacter spp. isolated from different growth positive 
specimens. 
 Number (%) of resistant organisms 
Antibiotics used P. aeruginosa (n=79) Acinetobacter spp. (n=117) 
Aminoglycosides 
Amikacin (30 µg) 20 (25.3) 62 (53) 
Gentamicin (10 µg) 24 (30.4) 67 (57.3) 
Tobramycin (10 µg) 23 (29.1) 65 (55.6) 
Penicillins with β-lactamase inhibitors 
Piperacillin-tazobactam (100/10 µg) 71 (89.9) 88 (75.2) 
Ampicillin-sulbactam (10/10 µg) - 23 (19.7) 
Carbapenems 
Meropenem (10 µg) 22 (27.8) 57 (48.7) 
Imipenem (10 µg) 15 (19) 57 (48.7) 
Cephems 
Ceftazidime (30 µg) 58 (73.4) 92 (78.6) 
Cefepime (30 µg) 54 (68.4) 89 (76.1) 
Cefotaxime (30 µg) - 96 (82.1) 
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 Number (%) of resistant organisms 
Antibiotics used P. aeruginosa (n=79) Acinetobacter spp. (n=117) 
Ceftriaxone (30 µg) - 95 (81.2) 
Fluoroquinolones 
Ciprofloxacin (5 µg) 30 (38) 66 (56.4) 
Levofloxacin (5 µg) 24 (30.4) 65 (55.6) 
Monobactams 
Aztreonam (30 µg) 52 (65.8) - 
Folate pathway inhibitors 
Trimethoprim-sulphamethoxazole  
(1.25/23.75 µg) 
- 79 (67.5) 
Tetracyclines 
Tetracycline (30 µg) - 70 (59.8) 
Lipopeptides 
Polymyxin B (300 Units) 0 (0) - 
 
Table 2. Distribution of isolates based on specimens and demographic profiles of patients. 
Variables 










Male 52 (65.8) 65 (55.6) 10 (66.6) 34 (59.6) 
Female 27 (34.2) 52 (44.4) 5 (33.3) 23 (40.4) 
Age group 
Newborn -12 (Children) 4 (5.1) 26 (22.2) 0 (0) 9 (15.8) 
13-19 (Adolescent) 6 (7.6) 9 (7.7) 2 (13.3) 5 (8.8) 
20-50 (Adult) 20 (25.3) 32 (27.4) 4 (26.7) 12 (21) 
>50 (Elderly) 49 (62) 50 (42.7) 9 (60) 31 (54.4) 
Specimens 
Respiratory specimens 44 (55.7) 48 (41) 8 (53.3) 33 (57.9) 
Pus 17 (21.5) 27 (23.1) 3 (20) 16 (28.1) 
Catheters 5 (6.3) 4 (3.4) 3 (20) 3 (5.2) 
Urine 10 (12.7) 11 (9.4) 1 (6.7) 0 (0) 
Blood and other body fluids 3 (3.8) 27 (23.1) 0 (0) 5 (8.8) 
Ward 
Intensive Care Unit (ICU) 29 (36.7) 48 (41) 11 (73.4) 31 (54.3) 
Surgery 13 (16.4) 22 (18.8) 2 (13.3) 15 (26.3) 
Paediatric 1 (1.3) 6 (5.1) 0 (0) 1 (1.7)) 
Obstetrics and Gynaecology (OBG) 1 (1.3) 6 (5.1) 0 (0) 0 (0) 
Medical 33 (41.8) 32 (27.4) 2 (13.3) 10 (17.5) 
Outpatient 2 (2.5) 3 (2.6) 0 (0) 0 (0) 
Legend: Respiratory specimens include endotracheal tube tips, endotracheal aspirate, tracheostomy tip, tracheostomy site swab; Other 




Metok et al.   Biofilm and MBL production among Pseudomonas and Acinetobacter 67 
MicroMedicine 2020; 8(2): 63-73 
Acinetobacter spp. isolates showed higher resistance towards cefotaxime (82.1%), followed by 
ceftriaxone (81.2%). Resistance rates of Acinetobacter spp. isolates towards meropenem and imipenem were 
48.7% each. Fifty-seven strains of Acinetobacter spp. were both imipenem and meropenem resistant (Table 
1). Of 117 Acinetobacter spp. tested, 49 (41.9%) were MDR, 23 (19.7) were XDR, and 45 (38.4%) were 
NMDR. Among 57 IRAS isolates, 23 were XDR, and 34 were MDR. 
A maximum number of imipenem resistant isolates were obtained from respiratory specimens (53.3% 
P. aeruginosa vs. 57.9% Acinetobacter spp.) followed by pus (20% P. aeruginosa vs. 28.1% Acinetobacter 
spp.). The distribution of IRPA (66.6%) and IRAS (59.6%) was higher among male than female patients. 
Moreover, the highest percentage of IRPA (60%) and IRAS (54.4%) was recovered from elderly patients. ICU 
was found to be the most common site for the isolation of IRPA (73.4%) and IRAS (54.3%) (Table 2). 
Results of combined disk test and E-test were concordant with all the imipenem resistant isolates 
showing 8 (53.3%) MBL producers among 15 IRPA and 22 (38.6%) MBL producers among 57 IRAS isolates 
(Table 3). All the MBL producer IRPA isolates were XDR, 100% resistant to all the tested antibiotics except 
polymyxin B (0%). In the case of 22 MBL producer IRAS isolates, 9 (40.9%) were XDR, and 13 (59.1%) 
were MDR. However, MBL producer IRAS isolates were relatively higher susceptible to ampicillin-
sulbactam (59%) followed tetracycline, ciprofloxacin, amikacin, and tobramycin (4%) while the rest of the 
antibiotics were 100% resistant. 
 
Table 3. Percentage of MBL producer isolates. 
Disc Diffusion Test 
E-test Combined Disc Test 
MIC (Minimum Inhibitory Concentration)  
of Imipenem (µg/ml) Number (%) of MBL 
positive 
Imipenem resistant isolates Sensitive (≤2) Intermediate (4) Resistant (≥8) 
IRPA (n=15) 0 4 11 8 (53.3) 
IRAS (n=57) 0 0 57 22 (38.6) 
Legend: MIC of imipenem; IRPA isolates (7 showed >256 µg/ml, 4 showed 128 µg/ml and 4 showed 6 µg/ml), IRAS isolates (36 showed 
>256 µg/ml, 12 showed 128 µg/ml and 9 showed 64 µg/ml). 
 
Table 4. Antibiotic resistance pattern of moderate and weak biofilm producer IRPA isolates. 
Antibiotics used 
Moderate biofilm producer IRPA 
(n=3) 
Weak biofilm producer IRPA  
(n=12) 
Amikacin 3 (100) 10 (83.3) 
Gentamicin 3 (100) 11 (91.6) 
Tobramycin 3 (100) 12 (100) 
Piperacillin-tazobactam 3 (100) 12 (100) 
Meropenem 3 (100) 11 (91.6) 
Imipenem 3 (100) 12 (100) 
Ceftazidime 3 (100) 12 (100) 
Cefepime 3 (100) 12 (100) 
Ciprofloxacin 3 (100) 12 (100) 
Levofloxacin 3 (100) 11 (91.6) 
Aztreonam 3 (100) 12 (100) 
Polymyxin B 0 (0) 0 (0) 
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Fifteen (100%) of IRPA isolates were biofilm producers; 3 (20%) were moderate, and 12 (80%) were 
weak biofilm producers. Though all the biofilm producer IRPA isolates were XDR, the resistance of amikacin, 
gentamicin, meropenem, and levofloxacin was relatively higher among moderate biofilm producers (100%) 
than weak biofilm producers (<92%) (Table 4). Among 57 IRAS, 47 (82.5%) were biofilm producers, of 
which 19 (33.3%) isolates were moderate, 28 (49.1%) strains were weak biofilm producers, and 10 (17.6%) 
were biofilm non-producers. Resistance to aminoglycosides, tetracycline, and ampicillin-sulbactam was 
comparatively higher among moderate biofilm producers (100%) than biofilm non-producer (<80%) IRAS 
isolates (Table 5). None of the imipenem resistant isolates were strong biofilm producers. The population of 
IRAS isolates that exhibited more stringent biofilm production likely contained a more significant proportion 
of XDR (Figure 1). The majority of MBL producer IRPA (62.5%) and IRAS (63.6%) isolates belonged to 
weak biofilm formers (Figure 2). 
 
Table 5. Antibiotic resistance pattern of different levels of biofilm producer and biofilm non-producer IRAS isolates. 
Antibiotics used 




Biofilm non- producer 
(n=10) 
Amikacin 19 (100) 27(96.4) 8 (80) 
Gentamicin 19 (100) 27 (96.4) 7 (70) 
Tobramycin 19 (100) 27 (96.4) 7 (70) 
Piperacillin-tazobactam 19 (100) 28 (100) 10 (100) 
Ampicillin-sulbactam 12(63.5) 11(39.3) 0 (0) 
Meropenem 19 (100) 28 (100) 10 (100) 
Imipenem 19 (100) 28 (100) 10 (100) 
Cefotaxime 19 (100) 28 (100) 10 (100) 
Ceftriaxone 19 (100) 28 (100) 10 (100) 
Ceftazidime 19 (100) 28 (100) 10 (100) 
Cefepime 19 (100) 28 (100) 10 (100) 
Ciprofloxacin 19 (100) 27 (96.4) 10 (100) 
Levofloxacin 19 (100) 28 (100) 10 (100) 




Figure 1. Distribution of resistance phenotypes among different biofilm production abilities  
of IRAS isolates displayed as a percentage stacked bar graph. 
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Figure 2. Percentage of MBL production among different biofilm production abilities of IRPA and IRAS isolates. 
 
4. DISCUSSION 
In the present study, the resistance rates of Acinetobacter spp. isolates towards meropenem and 
imipenem were 48.7% each, whereas that of P. aeruginosa isolates towards meropenem and imipenem were 
27.8% and 19.0%, respectively. The disparity between imipenem and meropenem susceptibility in a single 
isolate of P. aeruginosa is attributed to the chromosomal mediated mechanism, such as OprD loss leading to 
imipenem resistance and overexpression of efflux pumps adding to meropenem resistance [13]. In this study, 
27.8% of P. aeruginosa and 19.7% of Acinetobacter spp. were XDR, whereas 11.4% of P. aeruginosa and 
41.9% of Acinetobacter spp. were MDR. This rate was lower than those documented in the earlier study from 
Nepal [14,15].  
In this study, the highest number of imipenem resistant P. aeruginosa (53.3%) and Acinetobacter spp. 
(57.9%) were isolated from respiratory samples. It is well accepted that intubated patients with severe 
pulmonary disease are usually treated with prophylactic antibiotics, which increase the risk of resistance [15]. 
Similarly, the highest rate of infection by IRAS (54.4%) and IRPA (60%) strains were found among old age 
group patients. This might be due to their lowered immune system, which increases the risk of progression to 
infection. 73.4% of IRPA and 54.3% of IRAS isolates were recovered from ICU. The present finding is 
alarming as the use of broad-spectrum antibiotics without monitoring properly, and invasive procedures in 
ICU can be the epicenter of emergence and spread of highly drug-resistant strains. The study showed 53.3% 
of IRPA and 38.6% of IRAS isolates as MBL producers. The rate was lower than those documented in the 
previous study from Nepal [16]. In our study, all the MBL producer IRPA isolates were XDR, while 40.9% 
and 59.1% of MBL producer IRAS isolates were XDR and MDR, respectively. 
Exceedingly high, 100% of IRPA and 82.5% of IRAS isolates were biofilm producers. The majority of 
imipenem resistant strains (80% of IRPA and 49.1% of IRAS) were weak biofilm producers. Similarly, 62.5% 
of MBL producer IRPA and 63.6% of MBL producer IRAS isolates were weak biofilm-producing phenotype. 
Only Polymyxin B and ampicillin-sulbactam were found to be effective against biofilm cum MBL producer 
IRPA, and IRAS isolates, respectively. Similar to the present study, Rodríguez-Baño et al. [17] demonstrated 
that 63% of biofilm producer A. baumanii showed less frequently resistant to imipenem than those that were 
biofilm non-producers, indicating that degree of biofilm production by these strains are not dependent on 
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imipenem resistance. Likewise, Perez et al. [18] and Wang et al. [19] presented that carbapenem-resistant A. 
baumanii strains less likely to produce biofilm than carbapenem-susceptible strains. These results suggest that 
biofilm acts as a mechanism for bacteria to achieve better survival, notably in isolates with an insufficiently 
high resistance level [20]. In yet another study, Gallant et al. [21] showed that the expression of certain types 
of beta-lactamases diminished the formation of biofilm in P. aeruginosa and E. coli.  
In contrast, Chakraborty et al. [22] found a higher degree of biofilm formation among MBL producer 
P. aeruginosa isolates. Despite the inverse association between imipenem resistant (or MBL production) and 
degree of biofilm in our study, all the biofilm producer IRPA isolates were XDR, and more robust biofilm-
producing IRAS strains contained a larger proportion of XDR. Correspondingly, several studies [23-25] found 
that biofilm producer P. aeruginosa and A. baumannii were of higher drug-resistant. Notwithstanding, Qi et 
al. [26] accounted that most of A. baumanii isolates with a higher level of resistance appeared to form weaker 
biofilms. Several studies documented controversies between the ability of biofilm production and 
antimicrobial resistance. Therefore, further molecular analysis of these isolates would confirm the correlation 
between biofilm formation and antibiotic resistance. Moreover, it would provide new perspectives into the 
treatment and prevention against P. aeruginosa and Acinetobacter spp. ‘overlapping mechanisms’ related 
infections. 
5. CONCLUSION 
The study showed that XDR isolates of IRPA and IRAS have a high propensity to form a strong 
biofilm. However, the majority of imipenem resistant and MBL producer isolates were weak biofilm formers. 
Ampicillin-sulbactam and polymyxin B showed better susceptibility against such strains. This indicates the 
need for regular screening of biofilm production and monitoring antimicrobial resistance profiles of these 
isolates to restrict their uncontrolled spread and infection. 
Limitations: Further studies with adequate sample size, including imipenem susceptible strains, would help 
in testing the hypothesis of inferential statistics. Besides, molecular analysis of these isolates would confirm 
the correlation between biofilm formation and antimicrobial resistance.  
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IRPA: Imipenem Resistant Pseudomonas aeruginosa 
IRAS: Imipenem Resistant Acinetobacter spp. 
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MDR: Multidrug-Resistant  
NMDR: Non-Multidrug- Resistant 
MIC: Minimum Inhibitory Concentration 
EPS: Extracellular Polymeric Substance 
MHA: Mueller Hinton Agar 
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CLSI: Clinical Laboratory Standard Institute 
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